All-cause mortality and serum insulin-like growth factor I in primary care patients

Growth Hormone and IGF Research

Volumn 21, Issue 2, 2011, Pages 102-106

  Friedrich, N ^a   Schneider, H ^b   Dorr M ^a   Nauck, M ^a   Volzke H ^a   Klotsche, J ^c   Sievers, C ^c   Pittrow, D ^d   Bohler S ^d   Lehnert, H ^e   Pieper, L ^c   Wittchen, H U ^c   Wallaschofski, H ^a   Stalla, G K ^d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

Author keywords

DETECT; IGF I; Mortality; Primary care

Indexed keywords

SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADULT; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MORTALITY; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS;

EID: 79955479312     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.02.003     Document Type: Article

References (22)

1. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 2004, 25:102-152.
2. Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., Vandenbroucke J.P. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 2008, 93:61-67.
3. Mathioudakis N., Salvatori R. Adult-onset growth hormone deficiency: causes, complications and treatment options. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15:352-358.
4. Stochholm K., Christiansen J., Laursen T., Gravholt C.H. Mortality and reduced growth hormone secretion. Horm. Res. 2007, 68(Suppl 5):173-176.
5. Stochholm K., Gravholt C.H., Laursen T., et al. Mortality and GH deficiency: a nationwide study. Eur. J. Endocrinol. 2007, 157:9-18.
6. Laughlin G.A., Barrett-Connor E., Criqui M.H., Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 2004, 89:114-120.
7. Roubenoff R., Parise H., Payette H.A., et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am. J. Med. 2003, 115:429-435.
8. Andreassen M., Raymond I., Kistorp C., Hildebrandt P., Faber J., Kristensen L.O. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur. J. Endocrinol. 2009, 160:25-31.
9. Saydah S., Graubard B., Ballard-Barbash R., Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am. J. Epidemiol. 2007, 166:518-526.
10. Maggio M., Lauretani F., Ceda G.P., et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch. Intern. Med. 2007, 167:2249-2254.
11. Friedrich N., Haring R., Nauck M., et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J. Clin. Endocrinol. Metab. 2009, 94:1732-1739.
12. Wittchen H.U., Glaesmer H., Marz W., et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates - the DETECT program. Curr. Med. Res. Opin. 2005, 21:619-630.
13. Schneider H.J., Sievers C., Saller B., Wittchen H.U., Stalla G.K. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf.) 2008, 69:432-435.
14. Schneider H.J., Klotsche J., Saller B., et al. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. Eur. J. Endocrinol. 2008, 158:153-161.
15. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm. IGF Res. 2003, 13:113-170.
16. Donohue T.J., Dworkin L.D., Lango M.N., et al. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994, 89:799-809.
17. Ren J., Jefferson L., Sowers J.R., Brown R.A. Influence of age on contractile response to insulin-like growth factor 1 in ventricular myocytes from spontaneously hypertensive rats. Hypertension 1999, 34:1215-1222.
18. Tsukahara H., Gordienko D.V., Tonshoff B., Gelato M.C., Goligorsky M.S. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994, 45:598-604.
19. Walsh M.F., Barazi M., Pete G., Muniyappa R., Dunbar J.C., Sowers J.R. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996, 137:1798-1803.
20. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2007, 28:20-47.
21. Huang H., Tindall D.J. Dynamic FoxO transcription factors. J. Cell Sci. 2007, 120:2479-2487.
22. Paik J.H., Kollipara R., Chu G., et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007, 128:309-323.